blistering disorder. Aegle's IND for DEB has been cleared by the FDA and the company expects to enter the clinic by the 2H of 2020. Its proprietary platform isolation technology is cell-free and has the potential to demonstrate a safer, lower-cost means of harnessing the regenerative healing power of stem cells without using the cells. Aegle believes its EV therapy has the potential for functional regeneration and organization of complex tissue structures that can enhance healing, reduce scarring, minimize contraction, and improve overall cosmesis.

The company was founded in 2013 and is based in Miami, Florida.